New hope for arthritis sufferers: experimental drug GenSci120 enters Mid-Stage trial

NCT ID NCT07423533

Recruiting now Disease control Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called GenSci120 in 450 adults with moderate-to-severe rheumatoid arthritis who haven't improved with standard treatments. Participants receive either GenSci120, an existing drug (adalimumab), or a placebo for 14 weeks, followed by an extension period. The main goal is to see if GenSci120 reduces joint pain and swelling better than placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GenSci120 injection
What this could lead to: If successful, this could provide a new treatment option for people with rheumatoid arthritis who haven't responded well to existing drugs.
What could go wrong: This is an early Phase 2 trial, so the drug may not work better than existing treatments or could have unexpected side effects. Results are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.